The present invention relates to the use of compound 1 -[4-methylthiophenyl]-3-[3,5- dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1 -one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.La presente invención se refiere al uso del compuesto 1-[4-metiltiofenil]-3-[3,5-dimetil-4-carboxidimetilmetiloxifenil] prop-2-en-1-ona (Elafibranor o GFT505) para tratar enfermedades colestásicas y, más específicamente, CBP y/o CEP.